Quarterly report pursuant to Section 13 or 15(d)

SEGMENT INFORMATION (Tables)

v3.20.1
SEGMENT INFORMATION (Tables)
 3 Months Ended
Mar. 31, 2020
Segment Reporting [Abstract]  
Schedule of segment reporting information
The following table presents information by reportable operating segment for the three months ended March 31, 2020 and 2019 (in thousands):
 
Consumer Products
Segment
 
Specialty Pharmaceutical Segment
 
Consolidated Totals
Three months ended March 31, 2020:
 

 
 

 
 

Product sales, net
$
8,270

 
$
—

 
$
8,270

 
 
 
 
 
 
Gross profit
$
4,008

 
$
—

 
$
4,008

Research and development
305

 
1,204

 
1,509

Selling, general and administrative
7,810

 
9

 
7,819

Operating loss
$
(4,107
)
 
$
(1,213
)
 
$
(5,320
)
 
 
 
 
 
 
Three months ended March 31, 2019:
 
 
 
 
 
Product sales, net
$
14,911

 
$
—

 
$
14,911

 
 
 
 
 
 
Gross profit
$
10,559

 
$
—

 
$
10,559

Research and development
699

 
643

 
1,342

Selling, general and administrative
18,585

 
10

 
18,595

Operating loss
$
(8,725
)
 
$
(653
)
 
$
(9,378
)